About Us

Introduction


Observations that drug toxicities were, at times, more severe in our Asian patients spurred this desire to learn more about the Asian phenotype. Since our early start to investigate areas such as this, we have grown strength to strength in developing our research capabilities and interests. From demonstrating that various chemotherapy regimens for common cancers like breast and lung may result in different levels of side effects as compared with Caucasians, we have developed the international recognition in drug development to lead first-in-man early drug studies. This has had the additional benefit of offering suitable patients the opportunity to utilize cutting-edge and novel new drugs, long before these become available for routine use.

Today, HORG is recognized as being at the forefront of translational research in cancer therapeutics. Our researchers have the support of a committed team of doctors, administrators, clinical trial coordinators, nurse and pharmacists, in conducting their research. This model has helped allow dedicated care for our patients on clinical trials, focusing much needed time and effort where it is necessary, i.e. the patient.

Professor John Wong
Director of the National University Cancer Institute, Singapore (NCIS)

Department of Oncology


The Department of Haematology-Oncology was formerly known as the Department of Medical Oncology, that was originally formed in 1996. Today, the department is recognized as being at the forefront of translational research in cancer therapeutics. We aim to do better, from nurturing the next generation of investigators to continuing to help develop and increase our understanding of new therapies in Asia.

Placeholder
Dr John Wong

Learn More


Placeholder
Dr GOH Boon Cher

Learn More
Placeholder
Dr LEE Soo Chin

Learn More
Placeholder
Dr LIM Siew Eng

Learn More
Dr Ross SOO

Learn More
Placeholder
Dr Alvin WONG

Learn More


Placeholder
Dr YONG Wei Peng

Learn More
Placeholder
Dr TAN Sing Huang

Learn More
Placeholder
Dr CHIN Tan Min

Learn More

Placeholder
Dr LIM Yi Wan

Learn More

Placeholder
Dr David TAN

Learn More
Placeholder
Dr Andrea WONG

Learn More

Placeholder
Dr CHEE Cheng Ean

Learn More

Placeholder
Dr TAN Chee Seng

Learn More
Placeholder
Dr Angela PANG

Learn More
 

Department of Haematology


Placeholder
Dr CHNG Wee Joo

 Learn More

Placeholder
Dr LIU Te Chih

Learn More

Placeholder
Dr Koh Liang Piu

Learn More
Placeholder
Dr Chee Yen Lin

Learn More

Placeholder
Dr Michelle Poon

Learn More

Placeholder
Dr Ng Chin Hin

Learn More
Placeholder
Dr Lee Shir Ying

Learn More
Placeholder
Dr Yap Eng Soo

Learn More

Placeholder
Dr Esther Chan

Learn More

Placeholder
Dr Melissa Ooi

Learn More
 
 

Our Team


The Haematology-Oncology Research Group ( HORG) Trial Unit is headed by Ms. Joanne Chio who led a team responsible for conducting Phase I to III clinical trials in cancer. HORG conducts a number of first-in-man and first-in-class early drug studies.

HORG trial unit comprises of a dedicated team of clinical research coordinators, data coordinators , administrators and finance executives . It manages and supports all aspects of the clinical trial: from securing  ethics , regulatory , budget and legal approvals to the conduct of the study.